Type-I Collagen Polypeptide-Based Composite Nanofiber Membranes for Fast and Efficient Bone Regeneration

Area of Science:

• Biomaterials Science
• Tissue Engineering
• Regenerative Medicine

Background:

• Current bone defect treatments like allogeneic and autologous bone transplantation have limitations.
• Existing bone tissue engineering scaffolds often suffer from high biotoxicity and poor bioactivity, hindering bone regeneration.
• There is a need for advanced biomaterials that promote efficient and safe bone repair.

Purpose of the Study:

• To develop a novel composite nanofiber membrane for enhanced bone regeneration.
• To investigate the efficacy and safety of hydroxyapatite, EPO, and OGP co-doped collagen type-I polypeptide nanofiber membranes (NFMs).

Main Methods:

• Fabrication of composite NFMs using electrostatic spinning, incorporating hydroxyapatite, erythropoietin (EPO), and osteogenic growth peptide (OGP) into type-I collagen (Col I) polypeptide.
• In vitro cell experiments using rat bone marrow mesenchymal stem cells to assess cytotoxicity and osteogenic differentiation (qPCR, alkaline phosphatase, alizarin red S staining).
• In vivo animal studies to evaluate bone regeneration in critical-sized bone defects, including hematological and histological analyses.

Main Results:

• Composite NFMs exhibited low cytotoxicity and significantly promoted osteogenic differentiation of stem cells.
• In vitro assays confirmed high expression of osteogenic genes and formation of calcium nodules.
• Animal studies showed rapid and complete bone defect regeneration within two months, with hydroxyapatite acting as mineralization centers and Col I, EPO, and OGP promoting bone growth.

Conclusions:

• The designed NFMs, mimicking bone composition and incorporating mineralization centers and signaling molecules, effectively promote bone regeneration.
• This approach significantly shortens repair time and improves bone repair outcomes compared to traditional methods.
• The developed biomaterial shows promising potential for clinical applications in treating bone defects.